Skip to main content
OpenTrials
Completed

NCT Number: NCT01050569

Innovative Interventions for Smoking Cessation

The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine patch and very low nicotine content (VLNC) cigarettes compared to 21 mg nicotine patch only and very low nicotine content cigarette only on abstinence, time to relapse and toxicant levels. The study will determine if adding nicotine replacement medication to the very low content cigarettes (VLNC) will augment treatment compared to nicotine patch only or to very low nicotine content cigarettes only.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Minnesota, Duluth, Minnesota, United States

Loading trial locations.

About this study

The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine patch and very low nicotine content cigarette (VLNC) compared to the VLNC cigarette alone or 21 mg nicotine patch alone on abstinence, time to relapse and toxicant levels.

The following primary hypothesis will be tested:

Abstinence rates will be highest and the time to relapse will be the longest in the VLNC cigarettes plus nicotine patch condition compared to nicotine patch or VLNC cigarettes alone.

Other hypotheses include:

  • Greater positive subjective responses to cigarettes will be observed with VLNC cigarettes plus patch vs. VLNC cigarette;
  • Less drop-outs will be observed in the VLNC plus patch vs the other two conditions; and
  • Less compensatory smoking will be observed in the VLNC plus patch condition compared to VLNC cigarette alone condition.

Cigarette smokers will be randomized to:

  • VLNC cigarettes (which provide sensory behavioral aspects of smoking but with limited nicotine) plus nicotine patch for 6 weeks;
  • Nicotine patch for 6 weeks; or
  • VLNC cigarettes alone.

Outcome measures will include cessation assessed at the end of treatment as the primary endpoint and at 36 weeks post-treatment, time to lapse and relapse to usual brand cigarettes, and biomarkers of toxicant exposure. Predictors of abstinence and treatment response for each of the treatment conditions will be explored.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • a) Smoking at least 10 cigarettes daily for the past year;
  • b) In good physical health;
  • c) No contraindications for medicinal nicotine; and
  • d) Stable, good mental health.

Exclusion criteria

  • a) Subjects must not be using other tobacco or nicotine products.
  • b) Female subjects cannot be pregnant or nursing and must be using appropriate birth control.

Treatment and study plan

Nicotine patch

Drug

21 mg

Other names: Nicoderm CQ

VLNC Cigarette

Other

Cigarette where the tobacco contains <0.1 mg of nicotine yield.

Other names: Quest 3, Xodus

VLNC Cigarette Plus Nicotine Patch

Other

21 mg nicotine patch plus use of cigarette with tobacco containing <0.1 mg nicotine yield.

Other names: Nicoderm CQ, Quest 3, Xodus

Primary outcomes

  1. End of Treatment Abstinence Rate

    Time frame: 12 week

    Cotinine and carbon monoxide (CO) verified point prevalence abstinence

  2. End of Follow-up Abstinence Rates

    Time frame: 36 weeks

    CO- and cotinine-verified point prevalence abstinence

Secondary outcomes

  1. Exposure to Tobacco Toxicants

    Time frame: 6 weeks

  2. Time to Lapse or Relapse to Tobacco Use

    Time frame: 26 weeks

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Innovative Interventions for Smoking Cessation: Comparison of Very Low Nicotine Content Cigarettes Plus Nicotine Patch; Very Low Nicotine Content Cigarettes Alone or Nicotine Patch Alone

Important dates

Study start
2008
Primary completion
2011
Study completion
2012
First posted
Jan 15, 2010
Registry last updated
Nov 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.